Sarepta Therapeutics Quarterly Income Statement
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Sarepta Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Sarepta Therapeutics generated $401.3 million in revenue, down 34.3% from the same quarter a year earlier. Sarepta Therapeutics reported a net loss of $4.9 million, compared with net income of $196.9 million a year earlier. Operating margin was 3.3%.
Diluted earnings per share came in at -$0.05, down from $1.89.
Summary generated from market data by MetaCap's automated system. Methodology
Sarepta Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 401.25M | 730.80M | 442.93M | 399.36M | 611.09M | 744.86M | 658.41M | 467.17M | 362.93M | 413.46M | 396.78M | 331.82M |
| Revenue growth (YoY) | -34.34% | -1.89% | -32.73% | -14.52% | +68.38% | +80.15% | +65.94% | +40.79% | +38.93% | +63.10% | +53.54% | +44.10% |
| Gross Profit | — | — | -29.10M | 219.27M | 360.56M | 473.96M | 505.85M | 338.08M | 316.00M | 308.93M | — | — |
| Operating Expenses | — | — | 382.48M | 322.66M | 244.99M | 774.35M | 344.17M | 315.88M | 316.70M | 274.02M | — | — |
| Research & Development | 91.26M | 153.96M | 325.34M | 218.89M | 204.39M | 773.45M | 199.95M | 224.48M | 179.69M | 200.40M | 195.52M | 194.30M |
| Selling, General & Admin | 107.60M | 108.95M | 128.30M | 91.89M | 137.90M | 133.63M | 163.87M | 128.20M | 138.80M | 127.00M | 131.70M | 120.89M |
| Operating Income | 13.29M | 358.43M | -411.58M | -103.39M | 115.58M | -300.39M | 161.68M | 22.20M | -701.00K | 34.91M | 24.63M | -20.84M |
| Interest Expense | -21.51M | -21.71M | -40.04M | 1.90M | -5.23M | -4.50M | -32.31M | 4.92M | 4.83M | -4.17M | -38.79M | 5.23M |
| Other Income (Expense) | -15.04M | -15.26M | 133.29M | -90.66M | 38.06M | -83.13M | 10.06M | 11.81M | 14.28M | 6.54M | 15.75M | -12.33M |
| Pretax Income | -1.75M | 343.17M | -278.30M | -194.05M | 153.64M | -383.52M | 171.74M | 34.01M | 13.58M | 41.45M | 40.37M | -33.17M |
| Income Tax | 3.14M | 12.21M | 4.55M | -14.10M | -43.25M | 63.99M | 12.69M | 395.00K | 7.12M | 5.33M | -5.28M | 7.76M |
| Net Income | -4.89M | 330.96M | -412.23M | -50.57M | 196.89M | -447.51M | 159.05M | 33.61M | 6.46M | 36.12M | 45.66M | -40.94M |
| Net Income growth (YoY) | -102.48% | — | -359.18% | -250.45% | +2947.86% | -1338.98% | +248.37% | — | — | — | — | — |
| EPS (Basic) | -0.05 | 3.15 | -3.93 | -0.50 | 2.01 | -4.60 | 1.65 | 0.35 | 0.07 | 0.38 | 0.79 | -0.46 |
| EPS (Diluted) | -0.05 | 2.88 | -3.93 | -0.50 | 1.89 | -4.60 | 1.50 | 0.34 | 0.07 | 0.37 | 0.79 | -0.46 |
| Shares Outstanding (Basic) | 105.43M | 104.99M | — | 100.24M | 98.00M | 97.36M | — | 95.39M | 94.62M | 93.99M | — | 88.89M |
| Shares Outstanding (Diluted) | 105.43M | 121.92M | — | 100.24M | 106.62M | 97.36M | — | 100.45M | 99.14M | 99.11M | — | 88.89M |
| EBITDA | 23.70M | 369.03M | -406.33M | -84.94M | 126.42M | -290.41M | 172.14M | 32.00M | 8.02M | 43.65M | 36.00M | -9.91M |
| Gross Margin | — | — | -6.57% | 54.91% | 59.00% | 63.63% | 76.83% | 72.37% | 87.07% | 74.72% | — | — |
| Operating Margin | 3.31% | 49.05% | -92.92% | -25.89% | 18.91% | -40.33% | 24.56% | 4.75% | -19.00% | 8.44% | 6.21% | -6.28% |
| Net Margin | -122.00% | 45.29% | -93.07% | -12.66% | 32.22% | -60.08% | 24.16% | 7.19% | 1.78% | 8.74% | 11.51% | -12.34% |
This table shows 12 quarterly periods of Sarepta Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow SRPT's reporting calendar. What is a income statement?